Stem Cells Spin Valuation

Q: What is the Fair Price of SCS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SCS (PLN0.52) is trading above our estimate of [[fair value]] (PLN0.03)

Is SCS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SCS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SCS (PLN0.52) is trading above our estimate of fair value (PLN0.03)

Significantly Below Fair Value: SCS is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SCS?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for SCS. This is calculated by dividing SCS's market cap by their current preferred multiple.
What is SCS's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	zł21.49m

SCS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	51.5x
Enterprise Value/EBITDA	23.1x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does SCS's PB Ratio compare to its peers?

The above table shows the PB ratio for SCS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	6.5x
PUR Pure Biologics	2x	n/a	zł26.1m
GEN Genomed Spólka Akcyjna	3.9x	n/a	zł39.1m
GX1 genXone	1.6x	n/a	zł23.4m
RDG Read-Gene	18.5x	n/a	zł65.6m
SCS Stem Cells Spin	2.9x	n/a	zł21.5m

Price-To-Book vs Peers: SCS is good value based on its Price-To-Book Ratio (2.9x) compared to the peer average (6.5x).

Price to Earnings Ratio vs Industry

How does SCS's PE Ratio compare vs other companies in the European Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	30.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	30.8%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: SCS is expensive based on its Price-To-Book Ratio (2.9x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is SCS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SCS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.9x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SCS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.